Elevated alkaline phosphatase with raltegravir in a treatment experienced HIV patient

We describe an AIDS patient who developed elevated alkaline phosphatase levels after treatment with raltegravir. A Hispanic, 45-year-old, treatment-experienced male with genotypic/phenotypic resistance to multiple protease inhibitors, nucleoside reverse transcriptase inhibitors, and nonnucleoside re...

Full description

Saved in:
Bibliographic Details
Published inAIDS (London) Vol. 22; no. 17; pp. 2404 - 2405
Main Authors FLEISCHBEIN, Eric, O'BRIEN, John, MARTELINO, Ryan, FENSTERSHEIB, Martin
Format Journal Article
LanguageEnglish
Published Hagerstown, MD Lippincott Williams & Wilkins 12.11.2008
Subjects
Alkaline Phosphatase - metabolism
Antibiotics. Antiinfectious agents. Antiparasitic agents
Antiviral agents
Atazanavir Sulfate
Biological and medical sciences
CD4 Lymphocyte Count
Drug Interactions
Drug Resistance, Viral
HIV Infections - drug therapy
HIV Infections - genetics
HIV-1
Human immunodeficiency virus
Human viral diseases
Humans
Immunodeficiencies
Immunodeficiencies. Immunoglobulinopathies
Immunopathology
Infectious diseases
Male
Medical sciences
Middle Aged
Oligopeptides - adverse effects
Oligopeptides - therapeutic use
Pharmacology. Drug treatments
Pyridines - adverse effects
Pyridines - therapeutic use
Pyrrolidinones - adverse effects
Pyrrolidinones - therapeutic use
Raltegravir Potassium
Viral diseases
Viral diseases of the lymphoid tissue and the blood. Aids
Immunopathology
Alkaline phosphatase
Antiretroviral agent
Enzyme
Phosphoric monoester hydrolases
AIDS
Esterases
Immune deficiency
Infection
Integrase inhibitor
Treatment
Viral disease
Hydrolases
Antiviral
Raltegravir
Online AccessGet full text

Cover

More Information
Summary:We describe an AIDS patient who developed elevated alkaline phosphatase levels after treatment with raltegravir. A Hispanic, 45-year-old, treatment-experienced male with genotypic/phenotypic resistance to multiple protease inhibitors, nucleoside reverse transcriptase inhibitors, and nonnucleoside reverse transcriptase inhibitors, a viral load of 2368 copies/ml, and CD4 count of 20/ml, 2% (normal: 550-2000/ml and 32-62%, respectively) began treatment with raltegravir. Raltegravir was added to the patient's latest regimen of atazanavir, darunavir, ritonavir, tenofovir/emtricitabine combination, and zido-vudine, which he had been taking for over 6 months.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0269-9370
1473-5571
DOI:10.1097/QAD.0b013e328316eb91